Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure

Jonathan Z. Li, Roger Paredes, Heather J. Ribaudo, Evguenia S. Svarovskaia, Michael J. Kozal, Katherine H. Hullsiek, Michael D. Miller, David Bangsberg, Daniel R. Kuritzkes

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Objectives: To evaluate the risk of virologic failure conferred by suboptimal adherence to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and minority NNRTI resistance mutations. Design: Pooled analysis of the risk of virologic failure conferred by minority NNRTI resistance mutations and NNRTI adherence from three studies of treatment-naïve individuals initiating an NNRTI-based regimen. Methods: Participants from each study were categorized into both adherence quartiles (Q1-Q4) and four strata: at least 95%, 80-94%, 60-79%, and below 60%. Weighted Cox proportional hazard models were used to estimate the risk of virologic failure. Results: The majority of participants (N=768) had high measured adherence, but those in the lowest adherence quartile had the highest proportion of participants with virologic failure and the risk of virologic failure increased step-wise with adherence below 95%. Detection of minority NNRTI drug resistance mutations increased the proportion of participants with virologic failure across adherence quartiles (Cochran-Mantel-Haenszel P<0.001) and adherence strata [Cochran-Mantel- Haenszel P<0.001; <60% adherence, hazard ratio 1.7 (1.1-2.7), P=0.02; 60- 79% adherence, hazard ratio 1.2 (0.5-3.2), P=0.67; 80-94% adherence, hazard ratio 2.5 (0.98-6.3), P=0.06; ≥95% adherence, hazard ratio 3.6 (2.3-5.6), P<0.001]. On multivariate analysis, the effect of minority variants was also most prominent at higher levels of medication adherence. Conclusions: The presence of minority NNRTI resistance mutations and NNRTI adherence were found to be independent predictors of virologic failure, but also modify each other's effects on virologic failure. In addition to the focus on medication adherence counseling, ultrasensitive HIV-1 drug resistance assays could play a role in optimizing the success rates of first-line antiretroviral therapy.

Original languageEnglish (US)
Pages (from-to)185-192
Number of pages8
JournalAIDS
Volume26
Issue number2
DOIs
StatePublished - Jan 14 2012
Externally publishedYes

Fingerprint

Reverse Transcriptase Inhibitors
Mutation
Medication Adherence
Drug Resistance
Proportional Hazards Models
HIV-1
Counseling
Multivariate Analysis

Keywords

  • Antiretroviral therapy
  • HIV-1 drug resistance
  • Medication adherence
  • Minority variants
  • Virologic failure

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Li, J. Z., Paredes, R., Ribaudo, H. J., Svarovskaia, E. S., Kozal, M. J., Hullsiek, K. H., ... Kuritzkes, D. R. (2012). Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS, 26(2), 185-192. https://doi.org/10.1097/QAD.0b013e32834e9d7d

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. / Li, Jonathan Z.; Paredes, Roger; Ribaudo, Heather J.; Svarovskaia, Evguenia S.; Kozal, Michael J.; Hullsiek, Katherine H.; Miller, Michael D.; Bangsberg, David; Kuritzkes, Daniel R.

In: AIDS, Vol. 26, No. 2, 14.01.2012, p. 185-192.

Research output: Contribution to journalArticle

Li, JZ, Paredes, R, Ribaudo, HJ, Svarovskaia, ES, Kozal, MJ, Hullsiek, KH, Miller, MD, Bangsberg, D & Kuritzkes, DR 2012, 'Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure', AIDS, vol. 26, no. 2, pp. 185-192. https://doi.org/10.1097/QAD.0b013e32834e9d7d
Li, Jonathan Z. ; Paredes, Roger ; Ribaudo, Heather J. ; Svarovskaia, Evguenia S. ; Kozal, Michael J. ; Hullsiek, Katherine H. ; Miller, Michael D. ; Bangsberg, David ; Kuritzkes, Daniel R. / Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. In: AIDS. 2012 ; Vol. 26, No. 2. pp. 185-192.
@article{cf546765eaa0449c85c2cb0c6ae34edd,
title = "Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure",
abstract = "Objectives: To evaluate the risk of virologic failure conferred by suboptimal adherence to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and minority NNRTI resistance mutations. Design: Pooled analysis of the risk of virologic failure conferred by minority NNRTI resistance mutations and NNRTI adherence from three studies of treatment-na{\"i}ve individuals initiating an NNRTI-based regimen. Methods: Participants from each study were categorized into both adherence quartiles (Q1-Q4) and four strata: at least 95{\%}, 80-94{\%}, 60-79{\%}, and below 60{\%}. Weighted Cox proportional hazard models were used to estimate the risk of virologic failure. Results: The majority of participants (N=768) had high measured adherence, but those in the lowest adherence quartile had the highest proportion of participants with virologic failure and the risk of virologic failure increased step-wise with adherence below 95{\%}. Detection of minority NNRTI drug resistance mutations increased the proportion of participants with virologic failure across adherence quartiles (Cochran-Mantel-Haenszel P<0.001) and adherence strata [Cochran-Mantel- Haenszel P<0.001; <60{\%} adherence, hazard ratio 1.7 (1.1-2.7), P=0.02; 60- 79{\%} adherence, hazard ratio 1.2 (0.5-3.2), P=0.67; 80-94{\%} adherence, hazard ratio 2.5 (0.98-6.3), P=0.06; ≥95{\%} adherence, hazard ratio 3.6 (2.3-5.6), P<0.001]. On multivariate analysis, the effect of minority variants was also most prominent at higher levels of medication adherence. Conclusions: The presence of minority NNRTI resistance mutations and NNRTI adherence were found to be independent predictors of virologic failure, but also modify each other's effects on virologic failure. In addition to the focus on medication adherence counseling, ultrasensitive HIV-1 drug resistance assays could play a role in optimizing the success rates of first-line antiretroviral therapy.",
keywords = "Antiretroviral therapy, HIV-1 drug resistance, Medication adherence, Minority variants, Virologic failure",
author = "Li, {Jonathan Z.} and Roger Paredes and Ribaudo, {Heather J.} and Svarovskaia, {Evguenia S.} and Kozal, {Michael J.} and Hullsiek, {Katherine H.} and Miller, {Michael D.} and David Bangsberg and Kuritzkes, {Daniel R.}",
year = "2012",
month = "1",
day = "14",
doi = "10.1097/QAD.0b013e32834e9d7d",
language = "English (US)",
volume = "26",
pages = "185--192",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure

AU - Li, Jonathan Z.

AU - Paredes, Roger

AU - Ribaudo, Heather J.

AU - Svarovskaia, Evguenia S.

AU - Kozal, Michael J.

AU - Hullsiek, Katherine H.

AU - Miller, Michael D.

AU - Bangsberg, David

AU - Kuritzkes, Daniel R.

PY - 2012/1/14

Y1 - 2012/1/14

N2 - Objectives: To evaluate the risk of virologic failure conferred by suboptimal adherence to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and minority NNRTI resistance mutations. Design: Pooled analysis of the risk of virologic failure conferred by minority NNRTI resistance mutations and NNRTI adherence from three studies of treatment-naïve individuals initiating an NNRTI-based regimen. Methods: Participants from each study were categorized into both adherence quartiles (Q1-Q4) and four strata: at least 95%, 80-94%, 60-79%, and below 60%. Weighted Cox proportional hazard models were used to estimate the risk of virologic failure. Results: The majority of participants (N=768) had high measured adherence, but those in the lowest adherence quartile had the highest proportion of participants with virologic failure and the risk of virologic failure increased step-wise with adherence below 95%. Detection of minority NNRTI drug resistance mutations increased the proportion of participants with virologic failure across adherence quartiles (Cochran-Mantel-Haenszel P<0.001) and adherence strata [Cochran-Mantel- Haenszel P<0.001; <60% adherence, hazard ratio 1.7 (1.1-2.7), P=0.02; 60- 79% adherence, hazard ratio 1.2 (0.5-3.2), P=0.67; 80-94% adherence, hazard ratio 2.5 (0.98-6.3), P=0.06; ≥95% adherence, hazard ratio 3.6 (2.3-5.6), P<0.001]. On multivariate analysis, the effect of minority variants was also most prominent at higher levels of medication adherence. Conclusions: The presence of minority NNRTI resistance mutations and NNRTI adherence were found to be independent predictors of virologic failure, but also modify each other's effects on virologic failure. In addition to the focus on medication adherence counseling, ultrasensitive HIV-1 drug resistance assays could play a role in optimizing the success rates of first-line antiretroviral therapy.

AB - Objectives: To evaluate the risk of virologic failure conferred by suboptimal adherence to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and minority NNRTI resistance mutations. Design: Pooled analysis of the risk of virologic failure conferred by minority NNRTI resistance mutations and NNRTI adherence from three studies of treatment-naïve individuals initiating an NNRTI-based regimen. Methods: Participants from each study were categorized into both adherence quartiles (Q1-Q4) and four strata: at least 95%, 80-94%, 60-79%, and below 60%. Weighted Cox proportional hazard models were used to estimate the risk of virologic failure. Results: The majority of participants (N=768) had high measured adherence, but those in the lowest adherence quartile had the highest proportion of participants with virologic failure and the risk of virologic failure increased step-wise with adherence below 95%. Detection of minority NNRTI drug resistance mutations increased the proportion of participants with virologic failure across adherence quartiles (Cochran-Mantel-Haenszel P<0.001) and adherence strata [Cochran-Mantel- Haenszel P<0.001; <60% adherence, hazard ratio 1.7 (1.1-2.7), P=0.02; 60- 79% adherence, hazard ratio 1.2 (0.5-3.2), P=0.67; 80-94% adherence, hazard ratio 2.5 (0.98-6.3), P=0.06; ≥95% adherence, hazard ratio 3.6 (2.3-5.6), P<0.001]. On multivariate analysis, the effect of minority variants was also most prominent at higher levels of medication adherence. Conclusions: The presence of minority NNRTI resistance mutations and NNRTI adherence were found to be independent predictors of virologic failure, but also modify each other's effects on virologic failure. In addition to the focus on medication adherence counseling, ultrasensitive HIV-1 drug resistance assays could play a role in optimizing the success rates of first-line antiretroviral therapy.

KW - Antiretroviral therapy

KW - HIV-1 drug resistance

KW - Medication adherence

KW - Minority variants

KW - Virologic failure

UR - http://www.scopus.com/inward/record.url?scp=84155169026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84155169026&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e32834e9d7d

DO - 10.1097/QAD.0b013e32834e9d7d

M3 - Article

VL - 26

SP - 185

EP - 192

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 2

ER -